Daniil Gataulin Analyst PerformanceSenior Research Analyst, Ophthalmology at Chardan CapitalDaniil Gataulin is a stock analyst at Chardan Capital in the medical sector, covering 15 publicly traded companies. Over the past year, Daniil Gataulin has issued 46 stock ratings, including buy and hold recommendations. While full access to Daniil Gataulin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Daniil Gataulin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings46 Last 0 YearsBuy Recommendations91.30% 42 Buy RatingsCompanies Covered15 Unique Companies Ratings Distribution46RatingsDistribution of strong buy, buy, hold, and sell ratings by Daniil Gataulin.RatingPercentageCount Strong Buy0.0%0 ratings Buy91.3%42 ratings Hold8.7%4 ratings Sell0.0%0 ratingsOut of 46 total stock ratings issued by Daniil Gataulin at Chardan Capital, the majority (91.3%) have been Buy recommendations, followed by 8.7% Hold.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ15 companiesDaniil Gataulin, an analyst at Chardan Capital, currently covers 15 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies100.0%Daniil Gataulin of Chardan Capital specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE13 companies86.7%MED - DRUGS2 companies13.3% About Daniil GataulinDr. Daniil Gataulin is a Senior Research Analyst at Chardan covering Biotech companies with a focus on ophthalmology. Dr. Daniil Gataulin joined Chardan in the summer of 2021 as a VP, Senior Research Associate covering Biotechnology. Prior to Chardan, he held a Senior Research Associate position at Raymond James, where he covered SMID biotech companies with the focus on neurology, hematology, and gene therapy. Prior to his role at Raymond James, Dr. Gataulin studied the mechanism of DNA repair and recombination in the laboratory of Dr. Doug Bishop at the University of Chicago, where he discovered a novel role for ATP hydrolysis by a DNA repair/recombination protein. Dr. Gataulin holds a BS in Cell Molecular Biology from Grand Valley State University, Master’s degree in Biotechnology from Illinois Institute of Technology, and a PhD in Molecular Genetics and Cell Biology from the University of Chicago.Follow on LinkedIn Daniil Gataulin's Ratings History at Chardan Capital Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsOCGNOcugen9/19/2025Reiterated Rating$1.40$7.00Buy$0.0000.00% ROIOCULOcular Therapeutix9/15/2025Initiated Coverage$12.81$21.00Buy$0.0000.00% ROITRMLTourmaline Bio9/10/2025Downgrade$47.64$48.00Neutral$0.0000.00% ROIQUREuniQure9/8/2025Reiterated Rating$17.95$35.00Buy$0.0000.00% ROIRGNXREGENXBIO9/8/2025Reiterated Rating$9.71$52.00Buy$0.0000.00% ROIQUREuniQure8/29/2025Reiterated Rating$16.26$35.00Buy$0.0000.00% ROIOTLKOncobiologics8/28/2025Reiterated Rating$1.09$3.00Neutral$0.0000.00% ROIFBRXForte Biosciences8/15/2025Reiterated Rating$10.82$61.00Buy$0.0000.00% ROIZURAZura Bio8/15/2025Reiterated Rating$1.72$10.00Buy$0.0000.00% ROIOTLKOncobiologics8/15/2025Reiterated Rating$2.43$3.00Neutral$0.0000.00% ROIMGTXMeiraGTx8/15/2025Reiterated Rating$8.33$35.00Buy$0.0000.00% ROITRMLTourmaline Bio8/14/2025Reiterated Rating$21.77$70.00Buy$0.0000.00% ROIADVMAdverum Biotechnologies8/13/2025Reiterated Rating$2.58$33.00Buy$0.0000.00% ROICRVOCervoMed8/11/2025Reiterated Rating$9.85$15.00Buy$0.0000.00% ROIRGNXREGENXBIO8/8/2025Reiterated Rating$7.90$52.00Buy$0.0000.00% ROICGTXCognition Therapeutics8/8/2025Reiterated Rating$0.68$4.00Buy$0.0000.00% ROIEYPTEyepoint Pharmaceuticals8/7/2025Reiterated Rating$10.58$27.00Buy$0.0000.00% ROIOCGNOcugen8/4/2025Reiterated Rating$0.99$7.00Buy$0.0000.00% ROIQUREuniQure7/29/2025Lower Price Target$13.68$35.00Buy$0.0000.00% ROICLSDClearside Biomedical7/18/2025Downgrade$0.60Neutral$0.0000.00% ROIOCGNOcugen6/24/2025Reiterated Rating$0.98$7.00Buy$0.0000.00% ROIFBRXForte Biosciences6/24/2025Reiterated Rating$12.76$61.00Buy$0.0000.00% ROIRGNXREGENXBIO6/9/2025Reiterated Rating$9.61$52.00Buy$0.0000.00% ROIADVMAdverum Biotechnologies5/15/2025Reiterated Rating$1.88$33.00Buy$0.0000.00% ROIMGTXMeiraGTx5/14/2025Lower Price Target$5.15$35.00Buy$0.0000.00% ROIOCGNOcugen5/12/2025Reiterated Rating$0.67$7.00Buy$0.0000.00% ROIOCSOculis5/9/2025Boost Price Target$18.70$33.00Buy$0.0000.00% ROICGTXCognition Therapeutics5/8/2025Lower Price Target$0.35$4.00Buy$0.0000.00% ROIEYPTEyepoint Pharmaceuticals5/8/2025Lower Price Target$6.09$27.00Buy$0.0000.00% ROITRMLTourmaline Bio4/23/2025Initiated Coverage$17.32$70.00Buy$0.0000.00% ROIADVMAdverum Biotechnologies4/17/2025Lower Price Target$2.98$33.00Buy$0.0000.00% ROIOCSOculis4/17/2025Reiterated Rating$18.02$28.00Buy$0.0000.00% ROIQUREuniQure4/1/2025Initiated Coverage$10.60$38.00Buy$0.0000.00% ROIFBRXForte Biosciences4/1/2025Lower Price Target$7.43$61.00Buy$0.0000.00% ROICLSDClearside Biomedical3/28/2025Reiterated Rating$15.45$90.00Buy$0.0000.00% ROICGTXCognition Therapeutics3/21/2025Lower Price Target$0.43$8.00Buy$0.0000.00% ROIRGNXREGENXBIO3/20/2025Reiterated Rating$8.50$52.00Buy$0.0000.00% ROIRGNXREGENXBIO3/14/2025Reiterated Rating$6.55$52.00Buy$0.0000.00% ROIOCSOculis3/13/2025Reiterated Rating$18.84$28.00Buy$0.0000.00% ROIOCGNOcugen3/6/2025Boost Price Target$0.57$7.00Buy$0.0000.00% ROIEYPTEyepoint Pharmaceuticals3/6/2025Reiterated Rating$6.82$33.00Buy$0.0000.00% ROICGTXCognition Therapeutics2/26/2025Reiterated Rating$0.50$11.00Buy$0.0000.00% ROIMGTXMeiraGTx2/24/2025Reiterated Rating$7.30$36.00Buy$0.0000.00% ROIOCGNOcugen2/13/2025Reiterated Rating$0.66$6.00Buy$0.0000.00% ROIEYPTEyepoint Pharmaceuticals2/6/2025Reiterated Rating$7.80$33.00Buy$0.0000.00% ROIOCGNOcugen1/23/2025Reiterated Rating$0.75$6.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.